| Bioactivity | AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor with pIC50s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research[1][2]. | ||||||||||||
| Invitro | AZD2098 potently inhibits chemokine-induced cellular responses, with pIC50 of 7.5 and 6.3 against CCL22-induced Ca2+ influx in hCCR4-expressing CHO cells and CCL17- or CCL22-induced chemotaxis of primary human Th2 cells respectively[1]. | ||||||||||||
| In Vivo | AZD2098 (73.5-5.0 μg/kg; p.o.; BID; twice a day; 1 hour before and every 12 hours after antigen challenge) exhibits efficacy against antigen-induced inflammatory response among ovalbumin-sensitized rats, and the changes are first visible at a dose of 0.22 µmol/kg and maximal at 7.5 µmol/kg[1]. Animal Model: | ||||||||||||
| Name | AZD2098 | ||||||||||||
| CAS | 566203-88-1 | ||||||||||||
| Formula | C11H9Cl2N3O3S | ||||||||||||
| Molar Mass | 334.18 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kindon N, et al. Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists. ACS Med Chem Lett. 2017 Sep 1;8(9):981-986. [2]. Asher Mullard. Cancer charity sees success re-prioritizing industry's shelved compounds. Nat Rev Drug Discov. 2014 May;13(5):319-21. |
AZD2098
CAS: 566203-88-1 F: C11H9Cl2N3O3S W: 334.18
AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor withpIC50s of 7.8, 8.0, 8.0 and 7.6 for human
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.